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Abstract
Ras proteins regulate cell growth, differentiation and apoptosis. Their activities depend on their anchorage to the inner
surface of the plasma membrane, which is promoted by their common carboxy-terminal S-farnesylcysteine and either a
stretch of lysine residues (K-Ras 4B) or S-palmitoyl moieties (H-Ras, N-Ras and K-Ras 4A). We previously demonstrated
dislodgment of H-Ras from EJ cell membranes by S-trans,trans-farnesylthiosalicylic acid (FTS), and proposed that FTS
disrupts the interactions between the S-prenyl moiety of Ras and the membrane anchorage domains. In support of this
hypothesis, we now show that FTS, which is not a farnesyltransferase inhibitor, inhibits growth of NIH3T3 cells transformed
by the non-palmitoylated K-Ras 4B(12V) or by its farnesylated, but unmethylated, K-Ras 4B(12) CVYM mutant. The
growth-inhibitory effects of FTS followed the dislodgment and accelerated degradation of K-Ras 4B(12V), leading in turn to
a decrease in its amount in the cells and inhibition of MAPK activity. FTS did not affect the rate of degradation of the K-Ras
4B, SVIM mutant which is not modified post-translationally, suggesting that only farnesylated Ras isoforms are substrates
for facilitated degradation. The putative Ras-recognition sites (within domains in the cell membrane) appear to tolerate both
C15 and C20 S-prenyl moeities, since geranylgeranyl thiosalicylic acid mimicked the growth-inhibitory effects of FTS in
K-Ras 4B(12V)-transformed cells and FTS inhibited the growth of cells transformed by the geranylgeranylated K-Ras
4B(12V) CVIL isoform. The results suggest that FTS acts as a domain-targeted compound that disrupts Ras^membrane
interactions. The fact that FTS can target K-Ras 4B(12V), which is insensitive to inhibition by farnesyltransfarase inhibitors,
suggests that FTS may target Ras (and other prenylated proteins important for transformed cell growth) in an efficient
manner that speaks well for its potential as an anticancer therapeutic agent. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The small G-proteins K-Ras (the 4A and 4B iso-
forms), H-Ras and N-Ras are essential components
of signaling pathways that regulate cell growth, dif-
ferentiation and apoptosis [1^6]. These four proteins
share a high degree of amino acid identity (90%) and
have similar biochemical and biological activities
[7,8]. They operate as signal regulators of a large
number of cell-surface receptors where receptor sig-
naling through Ras involves activation of Ras ex-
change of GDP for GTP, interactions of Ras-GTP
with Ras-e¡ector molecules, and inactivation of Ras
by GTPase-activating proteins that facilitate GTP
hydrolysis by Ras [1,4,9]. Mutations in Ras genes,
mostly point mutations at codons 12, 13 and 61,
are common in many types of human cancers [7,8].
These mutations result in constitutively active ras
gene products which are permanently bound to
GTP and contribute to uncontrolled cell growth
and transformation [7,8].
Ras-dependent signaling and transforming activ-
ities require not only that Ras be bound to GTP,
but also that it be associated with the inner lea£et
of the plasma membrane [3,10^15]. Membrane an-
chorage of Ras proteins is promoted by their C-ter-
minal S-farnesylcysteine and by either a stretch of
lysine residues (K-Ras 4B isoform) or S-palmitoyl
moieties (H-Ras, N-Ras and K-Ras 4A isoforms)
[3,10^16]. The anchoring moieties of Ras proteins
also appear to target these proteins to the plasma
membrane [3,10^16], possibly to speci¢c membrane
microdomains [17^20].
On the assumption that Ras functions can be in-
hibited by dislodgment of the mature protein from its
putative membrane-anchorage domains, we recently
designed a series of organic compounds resembling
the farnesylcysteine of Ras proteins [21,22]. Among
these compounds, S-trans,trans-farnesylthiosalicylic
acid (FTS) was found to be a potent growth inhibitor
of H-Ras-transformed Rat-1 (EJ) ¢broblasts, a¡ect-
ing speci¢cally the membrane-bound H-Ras protein
in these cells [21,23^25]. FTS a¡ected H-Ras-mem-
brane interactions both in vivo and in vitro, dislodg-
ing the protein from its anchorage domains and fa-
cilitating its degradation [24]. These e¡ects appeared
to be speci¢c to the farnesylated Ras protein, as FTS
did not dislodge the prenylated GLQ subunits of het-
erotrimeric G-proteins from Rat-1 cell membranes
and had no e¡ect on the genetically engineered N-
myristoylated (unfarnesylated) H-Ras protein myr-
Ras in myr-Ras-transformed cells [24]. Growth of
the myr-Ras-transformed cells was not inhibited by
FTS [24]. Our earlier demonstration that FTS can
inhibit the growth of ¢broblasts transformed by
ErbB2 acting upstream of Ras, but not the growth
of cells transformed by v-Raf or by SV40 T-antigen
acting independently of Ras, suggested speci¢city of
FTS towards Ras and Ras driven cell growth [23].
Clearly then, FTS does not present a global growth
inhibitory e¡ect on normal cells or on every type of
transformed cell [23^25]. These results, as well as the
observed dislodgment of wild-type Ras isoforms in
untransformed Rat-1 cells, also suggested that FTS
might a¡ect all types of Ras proteins, not only the
activated H-Ras [24]. Moreover, because FTS is
structurally similar to the S-farnesyl cysteine com-
mon to all Ras proteins, we proposed that it may
interfere with anchorage domains that recognize the
S-prenyl moiety of Ras [24,25]. Because these possi-
bilities were not put to the test, we undertook to
examine the e¡ects of FTS and its analogs on
K-Ras 4B a non-palmitoylated Ras isoform in the
present study. Also, because H-ras mutations are rel-
atively rare in human cancers compared to mutations
in K- and N-ras genes [7,8], we considered it impor-
tant to examine whether FTS can a¡ect these Ras
proteins and their growth-promoting and transform-
ing activities. The potential importance of such stud-
ies is also highlighted by the results of recent experi-
ments demonstrating that K- and N-Ras proteins
can also be prenylated by the enzyme geranylgeranyl-
transferase I [26^29]. Since geranylgeranylated acti-
vated Ras proteins exhibit biological activity
[13,15,30], farnesyltransferase inhibitors may not di-
rectly block K- or N-Ras functions [3].
In the present study, we demonstrate that FTS
a¡ects various isoforms of activated K-Ras 4B in
NIH3T3 cells. We show that these e¡ects are man-
ifested in dislodgment of the constitutively active
K-Ras 4B(12V) from the cell membrane and its ac-
celerated degradation, inhibition of Ras-dependent
signaling to the mitogen-activated protein kinase
(MAPK) ERK, and inhibition of cell growth. This
result clearly distinguishes the action of FTS from
that of FTIs, which are currently in clinical trials
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for cancer treatment. Treatment of H-Ras with FTIs
easily results in a completely unprocessed, inactive
protein, whereas treatment of K-Ras 4B with FTIs
either fails to inhibit processing altogether or results
in an alternatively prenylated form of protein that
remains active. Since K-Ras 4B is the most com-
monly mutated form of ras in human tumors, the
ability of FTS to target both H- and K-Ras is a
very important ¢nding.
2. Materials and methods
2.1. Materials
[Q-32P]ATP (3000 Ci/mmol) was purchased from
Rotem Industries, Negev, Israel. 35S-Cysteine/meth-
ionine (express 35S-protein labeling) (1000 Ci/mmol)
was purchased from DuPont, New England Nuclear.
Anti-Ras antibodies (Pan-Ras antibody-3 (Pan-Ras
Ab) and Y13-259 Ab) were purchased from Onco-
gene Research Products. Anti-ERK2 antibodies were
purchased from Santa-Cruz. Goat anti-mouse IgG
horseradish peroxidase, myelin basic protein
(MBP), protein A Sepharose and protein G sephar-
ose were all from Sigma. Dulbecco’s modi¢ed Eagle’s
medium (DMEM) (high glucose), L-glutamine, pen-
icillin-streptomycin, trypsin/EDTA and fetal calf se-
rum (FCS) were from Biological Industries, Beit Ha-
Emek, Israel. Calf serum (CS) and G418 were pur-
chased from Gibco.
FTS, 5-£uoro-FTS (5-Fl-FTS), geranylthiosalicylic
acid (GTS) and geranylgeranyl thiosalicylic acid
(GGTS) were prepared by a general procedure and
puri¢ed and analyzed as described in detail elsewhere
[21,22].
2.2. Methods
2.2.1. Cell culture procedures
EJ cells, Rat-1 cells and myr-v-h-Ras(12V)-trans-
formed Rat-1 cells have been described previously
[23,24]. These cell lines were grown in DMEM,
10% FCS and 400 Wg/ml G418 at 37‡C in a humidi-
¢ed atmosphere of 95% air/5% CO2.
NIH3T3 cells stably expressing K-Ras 4B(12V),
K-Ras 4B(12V) 187Y (K-Ras 4B(12V) CVYM),
K-Ras 4B(12V) 185S (K-Ras 4B(12V) SVIM) and
K-Ras 4B(12V) 188L (K-Ras 4B(12V) CVIL) have
been described previously [14,15,31,32]. These cell
lines were grown in DMEM, 10% CS and 400 Wg/
ml G418 at 37‡C in a humidi¢ed atmosphere of 95%
air/5% CO2.
To estimate the e¡ects of FTS and its analogs on
cell growth, cells were plated at a density of 2500
cells per well in 24-well plates, to which either 0.1%
DMSO (carrier solution, control) or the indicated
concentration of the analog was added after 3 h.
Treated cells were grown for 5 days, detached from
the plates and counted.
2.2.2. Determination of Ras
Ras was assayed by enhanced chemiluminescence
(ECL) assays following immunoblotting [24]. K-Ras-
transformed NIH3T3 cells were plated at a density of
4U106 cells/10-cm dish. After 24 h, the cells were
treated for 15 h (dose^response experiments) or for
2, 4 or 24 h (time-course experiments) with FTS (0^
50 WM for dose response, 25 WM for time course) or
with 0.1% DMSO (control). The cells were then de-
tached from the dishes and washed in phosphate-
bu¡ered saline (PBS). All subsequent procedures
were carried out at 4‡C. Cell pellets were homogen-
ized in 750 Wl of homogenization bu¡er (20 mM Tris-
HCl pH 7.6, 5 Wg/ml leupeptin, 5 Wg/ml pepstatin,
1 mM benzamidine, 1 mM phenylmethylsulfonyl £u-
oride, 5 units/ml aprotinin and 10 mM MgCl2) and
the total amount of protein was determined. FTS
had no e¡ect on the total amount of protein per
cell. Total cell membrane (P100) and total cytosol
(S100) fractions were obtained by centrifugation at
100 000Ug (30 min). Following resuspension of the
P100 fraction in 750 Wl of homogenization bu¡er,
S100, P100 and the total homogenate were placed in
75 Wl ofU10 solubilization bu¡er (100 mM Tris-HCl
pH 7.5, 1.5 M NaCl, 10% Triton X-100, 5% Na-
deoxycholate). Samples were frozen for 1 h at
370‡C and then thawed. Insoluble material was re-
moved by centrifugation for 10 min at 10 000Ug and
the clear supernatants were used. Samples of the to-
tal cell homogenate (15 Wg protein) or of P100 and
S100 fractions (10 to 30 Wg protein) were separated by
12.5% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (mini-gel) and blotted
onto nitrocellulose paper. The paper was blocked
with 1.5% skim milk in Tris-bu¡ered saline pH 7.6
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(containing 0.05% Tween-20 and 150 mM NaCl)
overnight, then incubated for 1.5 h with 1:2000 di-
lution of Pan-Ras Ab in the same bu¡er. Immuno-
blots were then incubated for 1 h with 1:7500 dilu-
tion of anti-mouse IgG horseradish peroxidase
conjugate and subjected to enhanced chemilumines-
cence (ECL) assays. Bands were quanti¢ed by densi-
tometry on a BioImaging System 202D System (Dyn-
co-Renium, Jerusalem) using Tina 2.0 software (Ray
Tests).
Release of Ras from the membranes in a cell-free
system was assayed as described previously [24].
Brie£y, 15 Wg of membrane protein (P100 fraction)
were incubated for 60 min at 37‡C in 100 Wl of bu¡er
A (10 mM Tris-HCl, pH 8.5, 0.32 M sucrose, 1 mM
EDTA, 5 Wg/ml pepstatin, 5 units/ml aprotinin, 5 Wg/
ml leupeptin, 1 mM phenylmethylsulfonyl £uoride,
1 mM benzamidine and 1 mM MgCl2) containing
2% DMSO and 25 WM FTS or in 100 Wl of bu¡er
A containing 2% DMSO only (control). The reaction
mixture was then diluted by the addition of 900 Wl of
bu¡er B (10 mM Tris-HCl pH 8.5 containing only
the anti-proteases and 10 Wg bovine serum albumin).
After standing for 5 min at room temperature, the
samples were centrifuged (100 000Ug, 30 min), and
membrane pellets were subjected to the direct immu-
noblotting assay as described above. Assays were
performed in duplicate.
2.2.3. Ras degradation
The rate of Ras degradation was determined by
pulse-chase experiments [24]. Cells stably expressing
K-Ras 4B(12V) or K-Ras 4B(12V) SVIM were plated
at a density of 5U106 cells/10-cm dish in DMEM,
10% CS. One day after plating, the cells were starved
of serum and methionine and pulsed with 200 WCi/ml
35S-cysteine/methionine (1000 Ci/mmol, DuPont
NEN) for 6 h. The cells were then chased by removal
of the medium and addition of fresh medium (con-
taining methionine) and 25 WM FTS or 0.1% DMSO
(control). At zero time or at the indicated time peri-
ods, the cells were detached, washed in PBS and
homogenized in 500 Wl of homogenization bu¡er,
and the total amount of protein was determined.
Following the addition of 50 Wl ofU10 solubilization
bu¡er containing 1% SDS, the samples were frozen
for 1 h at 370‡C and then thawed. Insoluble materi-
al was removed by centrifugation at 10 000Ug for
10 min. The supernatant was incubated with 2 Wg
of naive rat IgG and 40 Wl of 10% protein G agarose
in a total volume of 500 Wl of solubilization bu¡er
containing 1% SDS. The precleared samples were
incubated for 12 h with 2 Wg of Y13-259 anti-Ras
antibodies coupled to agarose beads. The beads were
then precipitated, washed four times with 1 ml of
solubilization bu¡er containing 1% SDS and twice
with 1 ml of 20 mM Tris-HCl pH 7.6, and resus-
pended in 25 Wl of SDS sample bu¡er. Proteins
were separated by 12.5% SDS-PAGE (mini-gel),
stained, destained and dried. The dried gels were ex-
posed to X-ray ¢lm for 3^5 days and bands were
analyzed as described above.
2.2.4. Determination of ERK activity
K-Ras 4B(12V) or K-Ras 4B(12V) CVYL cells
were plated at a density of 1U106 cells/10 cm dish
in DMEM, 10% CS. One day after plating, FTS (5^
50 WM) or 0.1% DMSO (control) was added to the
cells in the medium for 18 h. ERK activity was then
assayed in the cell lysates. To each dish was added
1 ml of ERK lysis bu¡er (50 mM L-glycerophos-
phate, 1.5 mM EGTA, 2 mM sodium orthovanadate,
1 mM dithiothreitol, 2 Wg/ml leupeptin, 2 Wg/ml
aprotinin, 1 mM benzamidine and 1% NP-40), and
the dishes were kept on ice for 10 min. The cell
lysates were collected into Eppendorf tubes, vortexed
and centrifuged at 10 000Ug for 10 min at 4‡C. The
supernatants were collected. Samples of 500 Wg pro-
tein were then incubated for 2 h at 4‡C with 5 Wl of
anti-ERK-2 Ab (Santa Cruz) and 30 Wl of protein
A-Sepharose beads (diluted 1:1 in ERK lysis bu¡er).
The supernatant was discarded and the beads were
washed three times with ERK lysis bu¡er, followed
by two washes with kinase bu¡er (30 mM Tris-HCl
pH 8.0, 20 mM MnCl2, 2 mM MgCl2). Following
the addition to each sample of 30 Wl of complete
kinase bu¡er (containing the above kinase bu¡er
and 15 Wg MBP, 10 WM ATP and 5 WCi Q32P-ATP
(3000 Ci/mmol), samples were incubated for 30 min
at 37‡C. The reaction was stopped by the addition of
6 Wl of 6ULaemmli sample bu¡er and heating for
5 min at 95‡C. Following a short spin, the super-
natant was collected and the proteins were separated
by SDS-PAGE (15% acrylamide) on mini-gels. Phos-
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phorylated MBP was visualized by autoradiography
of the dried gels on X-ray ¢lms and quanti¢ed by
densitometric analysis, as detailed above.
3. Results
3.1. Dislodgment and accelerated degradation of
K-Ras 4B(12V)
H- and N-Ras proteins, unlike K-Ras 4B, which is
farnesylated, are both farnesylated and palmitoylated
[10^16]. We showed previously that FTS, whose
structure resembles the farnesylcysteine of Ras, can
interfere with H-Ras^membrane interactions [23,24].
If this interference is related primarily to the farnesyl
anchoring moiety of Ras, than FTS can be expected
to interfere with K-Ras 4B-membrane interactions as
well. To examine this possibility, we used NIH3T3
cells stably expressing the activated Ras mutant
K-Ras 4B(12V). Ras proteins in the cells were deter-
mined by Western immunoblotting/ECL assays with
Pan Ras Ab [24].
In agreement with earlier studies [14], the cells
overexpressed the K-Ras 4B(12V) protein, migrated
more slowly than the endogenous p21 Ras proteins
6
Fig. 1. Dislodgment of K-Ras 4B(12V) from membranes of
K-Ras 4B(12V)/NIH3T3 cells. (A) Dislodgment of Ras from
cell membranes in a cell-free system. Membranes of K-Ras
4B(12V)/NIH3T3 cells, H-Ras-transformed EJ cells and myr-
Ras-transformed cells were prepared as described in Section 2.
The membranes (15 Wg protein) were incubated for 60 min at
37‡C in the absence or in the presence of 25 WM FTS in 100 Wl
Tris-HCl bu¡er pH 8.5 containing anti-proteases, diluted 10-
fold, and collected after centrifugation at 100 000Ug, as de-
scribed in Section 2. Ras proteins in the membranes were then
determined by Western immunoblotting/ECL assays with pan-
Ras antibodies, as described in Section 2. Immunoblots of a
typical experiment are shown. Similar results were obtained in
two additional experiments. The mean decrease in K-Ras
4B(12V) and in H-Ras(12V) was 80 þ 12% and 75 þ 8%, respec-
tively. No decrease was detected in myr-Ras. (B) Time-depend-
ent dislodgment of Ras in K-Ras 4B(12V)/NIH3T3 cells by
FTS. NIH3T3 cells stably expressing K-Ras 4B(12V) were
plated at a density of 4U106 cells/10-cm dish and grown in
10% CS/DMEM. After 24 h, either the carrier (0.1% DMSO)
or FTS (25 WM) was added. Cells were homogenized at the
times indicated and Ras proteins were determined in the partic-
ulate fraction (P100) and in the cytosolic fraction (S100) by im-
munoblotting/ECL assays as described in A and in Section 2.
The ¢gure shows immunoblots of a typical experiment, where
15 Wg protein of P100 fractions and 30 Wg protein of S100 frac-
tions were loaded onto the gels. Densitometric analysis of the
results using the TINA program, and of two additional experi-
ments yielding similar results, indicated that FTS induced a de-
crease of 30 þ 12% (n = 3) and 60 þ 8% (n = 3) in the amounts of
K-Ras 4B(12V) after 4 and 24 h, respectively. The total amount
of K-Ras 4B(12V) in the S100 fractions was small (6 10% of
the amount in fraction P100) even in FTS-treated cells, although
relative to control there was a signi¢cant increase of 5 þ 2.5
fold (n = 3) in the amount of K-Ras 4B(12V) in S100 after 2 h
of FTS treatment. (C) FTS does not a¡ect the total membrane
protein. Cells were treated for 24 h with 25 WM FTS or with
0.1% DMSO as described in B. Total protein in the particulate
fraction (P100) and in cytosolic fraction (S100) was determined
by Coomassie blue staining. The ¢gure shows gel of a typical
experiment, were 7.5 Wg protein of P100 fraction and 15 Wg pro-
tein of S100 fraction were loaded onto the gel.
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or the H-Ras protein in Rat-1 (EJ) cells due to its
extra leader sequence. Experiments using a cell-free
system to assay the dislodgment of Ras [24] showed
that FTS (25 WM) induced a 70 þ 8% reduction in the
amount of membrane-bound K-Ras (12V) (Fig. 1A).
This e¡ect was similar to that observed under the
same conditions with H-Ras ([24], see also Fig.
1A). It should be noted that FTS did not induce
any reduction in the amount of N-myristoylated (un-
farnesylated) Ras under the same cell-free assay con-
ditions (Fig. 1A).
The e¡ects of FTS on K-Ras 4B(12V) were further
examined in intact cells exposed to 25 WM FTS for 2,
4, and 24 h. As shown in Fig. 1B, this treatment
caused a time-dependent decrease in membrane-
bound K-Ras 4B(12V) (100 000Ug pellet, P100),
while it did not a¡ect the total membrane protein
Fig. 3. FTS does not a¡ect the rate of degradation of unprocessed K-Ras 4B(V12) SVIM. K-Ras 4B(12V) SVIM/NIH3T3 cells were
subjected to 35S-cysteine pulse-chase experiments under the conditions described in Fig. 2. Results of a typical experiment (upper pan-
el) and densitometric analysis of data obtained in two experiments are presented as the ratio of values obtained at the indicated times
to values obtained at zero time.
Fig. 2. FTS facilitates degradation of K-Ras 4B(12V). K-Ras
4B(12V)/NIH3T3 cells (5U106 cells/10 cm dish) were pulsed
with 35S-cysteine/methionine in serum-free and cysteine/methio-
nine-free medium for 6 h and then chased in serum-free me-
dium, in the absence or in the presence of 25 WM FTS, for 0
12 h. Ras proteins were immunoprecipitated from total cell ho-
mogenates as described in Section 2. The immunoprecipitated
proteins were separated by SDS-PAGE (12.5%), and gels were
exposed to X-ray ¢lm for 48 h. The ¢gure shows the results of
a typical experiment (upper panel), and densitometric analysis
of data from four separate experiments presented as the ratios
of values obtained at the indicated times to values obtained at
zero time (mean þ S.D.).
6
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dislodgment (Fig. 1C). The decrease of membrane
bound K-Ras 4B(12V) was signi¢cant (30 þ 12%)
after 4 h of treatment and was more pronounced
(60 þ 8%) after 24 h. K-Ras 4B(12V) did not accu-
mulate in the cytosol following FTS treatment (Fig.
1B), though a signi¢cant transient increase in cyto-
solic K-Ras 4B(12V) was observed after treatment
with FTS for 2 h. These results suggested that FTS
induces dislodgment of K-Ras 4B from the cell mem-
brane and that the dislodged protein becomes suscep-
tible to proteolytic degradation. To test the latter
possibility, we performed pulse-chase experiments.
The cells were pulsed with 35S-cysteine/methionine
for 6 h and then chased in the presence or in the
absence of 25 WM FTS. Ras proteins were then im-
munoprecipitated from the cell lysates, separated by
SDS-PAGE and determined by autoradiography.
The half-life of 35S-labeled-K-Ras 4B(12V) was
found to be 10^12 h in the control cells and 3^4 h
in the FTS-treated cells (Fig. 2), indicating that FTS
had increased the rate of K-Ras 4B(12V) degrada-
tion. To examine whether the e¡ects of FTS were
speci¢c to the mature farnesylated K-Ras 4B(12V)
protein, we performed a similar set of pulse-chase
experiments with cells expressing K-Ras 4B(12V)
SVIM. This Ras isoform, with its C185CS mutation,
is not farnesylated [31]. As shown in Fig. 3, the 35S-
labeled K-Ras 4B(12V) SVIM appeared to be rela-
tively stable and did not undergo degradation for at
least 12 h, by which time the normally processed 35S-
labeled K-Ras 4B(12V) had already decayed to about
50% of its starting level (Fig. 2). FTS did not in-
crease the rate of degradation of the unprocessed
K-Ras 4B(12V) SVIM isoform (Fig. 3).
3.2. FTS induces a decrease in the total amount of
methylated and unmethylated K-Ras 4B(12V)
isoforms and inhibits MAPK
The above ¢ndings showed that FTS can dislodge
K-Ras 4B(12V) from the cell membrane in a cell-free
system and in intact cells, rendering the processed ^
but not the unprocessed ^ Ras protein susceptible to
proteolytic degradation in the cells. These results
suggested that FTS would induce a decrease in the
total amount of cellular K-Ras 4B(12V) by facilitat-
ing its degradation. When K-Ras 4B(12V)/NIH3T3
cells were incubated for 24 h with 5^50 WM FTS, a
dose-dependent decrease in the total amount of cel-
lular K-Ras 4B(12V) was indeed observed (Fig. 4A).
It is important to note, however, that while FTS does
not inhibit Ras farnesylation [23], it can inhibit Ras
methylation in vitro [21,22] and ^ at relatively high
concentrations (s 50 WM) ^ also in intact cells [23].
To examine whether the FTS-induced decrease in K-
Ras 4B(12V) (Fig. 4A) is associated with inhibition
of Ras methylation, we used cells stably expressing
K-Ras 4B(12V) CVYM. This K-Ras 4B mutant
undergoes farnesylation, but because of its I187CY
mutation there is no further processing [14]. The
K-Ras 4B(12V) CVYM mutant has a slower gel mi-
gration due to its extra leader sequence, as in the
Fig. 4. Dose-dependent decrease in the amount of K-Ras
4B(12V) and K-Ras 4B(12V) CVYM expressed by NIH3T3
cells. K-Ras 4B(12V)/NIH3T3 cells (A) or K-Ras(12V) CVYM/
NIH3T3 cells (B) were grown for 15 h in the presence of 0.1%
DMSO (control) or the indicated concentrations of FTS. Ras
proteins were then determined in whole-cell homogenates by
immunoblotting/ECL assay, as described for Fig. 1. The immu-
noblot data (shown in insets) and the data of two additional
experiments were analyzed densitometrically, and the mean val-
ues ( þ S.D.), expressed as percentages of control, were plotted
as a function of FTS concentration.
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K-Ras 4B(12V) mutant, and because its VYM is not
removed [14]. NIH3T3 cells stably expressing K-Ras
4B(12V) CVYM were exposed to di¡erent concentra-
tions of FTS (5^50 WM) for 24 h and the total
amount of K-Ras 4B(12V) CVYM was then deter-
mined by Western immunoblotting/ECL assays with
Pan Ras Ab. As shown in Fig. 4B, FTS caused a
dose-dependent decrease in the total amount of
K-Ras 4B(12V) CVYM. These results suggested
that the e¡ects of FTS on K-Ras 4B(12V) are inde-
pendent of the proteolytic removal of its VIM tripep-
tide and of carboxyl methylation.
The experiments described above showed that FTS
can induce a signi¢cant (40^60%) reduction in the
amounts of K-Ras 4B(12V) and K-Ras 4B(12V)
CVYM. To ¢nd out whether the reduced amount
of Ras in cells expressing these Ras mutants is man-
ifested in Ras-dependent signaling, we next examined
the e¡ects of FTS on the MAPK ERK, which is
required for cell growth and transformation [33,34].
Following treatment of the cells for 15 h with 5^50
WM FTS, ERK1 and 2 were immunoprecipitated
from the cell lysates with anti-ERK Ab. ERK activ-
ity was determined with MBP as a substrate and
ERK protein was determined by immunoblotting as-
says with anti-ERK Ab [35]. Results of a typical
experiment show that FTS caused a decrease in
ERK activity in K-Ras 4B(12V)/NIH3T3 cells with-
out an e¡ect on the total amount of ERK protein
(Fig. 5). Similar results were obtained with K-Ras
4B(12V) CVYM/NIH3T3 cells. As shown in Fig. 6,
FTS caused a dose-dependent decrease in ERK ac-
tivity of both K-Ras 4B(12V)/NIH3T3 cells (Fig. 6A)
and of K-Ras 4B(12V) CVYM/NIH3T3 cells (Fig.
6B).
3.3. S-Prenyl analogs speci¢cally inhibit growth of
cells transformed by K-Ras 4B(12V) isoforms
The above ¢ndings that FTS can induce a decrease
in K-Ras 4B(12V) and inhibit MAPK in cells ex-
Fig. 6. Dose-dependent inhibition of ERK activity by FTS in
K-Ras 4B(12V)/NIH3T3 cells and in K-Ras 4B(12V) CVYM/
NIH3T3 cells. K-Ras 4B(12V)/NIH3T3 cells (A) and K-Ras
4B(12V) CVYM/NIH3T3 cells (B) were plated at a density of
1U106 cells/10-cm dish and grown for 15 h in DMEM/10% CS
in the absence or in the presence of the indicated concentra-
tions of FTS. ERK1 and 2 were immunoprecipitated from the
cell lysates and ERK activity was determined with MBP as a
substrate, as described in Section 2. Phosphorylated MBP
bands were detected by autoradiography and quanti¢ed by den-
sitometric analysis. Data obtained in three separate experiments
are presented as the ratios (means þ S.D.) of values recorded at
the indicated concentrations of FTS and in the control cells.
Fig. 5. FTS inhibits ERK activity in K-Ras 4B(12V)/NIH3T3
cells. K-Ras 4B(12V)/NIH3T3 cells were plated at a density of
1U106 cells/10-cm dish and grown for 15 h in DMEM/10% CS
in the absence or in the presence of the indicated concentra-
tions of FTS. The cells were lysed and ERK protein in samples
of the cell lysate was determined by immunoblotting with anti-
ERK Ab. ERK1 and 2 were immunoprecipitated from the cell
lysates and ERK activity was determined with MBP as a sub-
strate, as described in Section 2. The ¢gure shows phosphoryl-
ated MBP bands detected by autoradiography (A), and ERK
protein bands detected with anti-ERK Ab (B).
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pressing K-Ras 4B isoforms suggested that these ef-
fects might also be manifested in the inhibition of cell
growth. This possibility was examined in cells grown
in DMEM/10% CS in the absence and in the pres-
ence of FTS or its analogs. In agreement with pre-
vious studies [14], both the K-Ras 4B(12V)/NIH3T3
cells and the K-Ras 4B(12V) CVYM/NIH3T3 pre-
sented transformed phenotypes forming multilayer
clumps of highly refractile spindle-like cells, indica-
tive of malignant transformation (see, for example,
control cells in Fig. 7). When the transformed cells
were grown for 5 days in the presence of FTS (5^25
WM), a signi¢cant reduction in the number of cells
was evident (Fig. 7). At the concentration range of
5^25 WM FTS did not exert cytotoxic e¡ects, as de-
termined separately by Trypan blue exclusion stain-
ing (not shown). A low degree of cytotoxicity
(V10%) was observed at 50 WM FTS. Quantitative
estimations of inhibition of cell growth by FTS were
obtained by direct counting. Results of typical ex-
periments (Fig. 8A) show that FTS inhibited, in a
dose-dependent manner, growth of both the K-Ras
4B(12V)/NIH3T3 cells and the K-Ras 4B(12V)
CVYM/NIH3T3 cells. Both cell lines appeared to
display similar sensitivity to FTS, where 40^60% in-
hibition of cell growth was apparent at 25^50 WM
FTS (Fig. 8A). In agreement with previous results
[23], FTS had no e¡ect on the growth of the parental
NIH3T3 cells at concentrations of 5^25 WM and only
a small inhibitory e¡ect (10^20%) at 50 WM (Fig.
8A). Similarly, FTS did not a¡ect the growth of
NIH3T3 cells stably expressing the unprocessed
K-Ras 4B(12V) SVIM mutant (Fig. 8B).
Next we examined the speci¢city of the inhibitory
e¡ect of FTS. In these experiments, cells that express
the normally processed K-Ras 4B(12V) isoform were
exposed to S-prenyl analogs other than FTS. As
shown in Fig. 8C, N-acetyl-S-farnesylcysteine
(AFC), previously shown to lack growth-inhibitory
e¡ects in H-Ras transformed cells [25], also did not
inhibit growth of the K-Ras 4B(12V)-transformed
cells. Similarly, the C10 geranyl analog GTS did not
inhibit growth of these cells, but the C20 geranylger-
anyl derivative GGTS and the 5-£uoro analog of
FTS were as potent as FTS (Fig. 8C). As shown in
Fig. 9A, GGTS (50 WM) also induced a signi¢cant
decrease (40%) in membrane-associated K-Ras
4B(12V). These structure^function relationships,
Fig. 7. Typical photomicrographs of control K-Ras 4B(12V)/NIH3T3 cells and of cells treated with FTS. Cells were plated at a den-
sity of 2500 cells per well in 24-well plates and grown for 5 days in the presence of 0.1% DMSO (control) or the indicated concentra-
tions of FTS, as described in Section 2, then photomicrographed (magni¢cation U100).
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which resemble those observed in H-Ras-trans-
formed Rat-1 cells [25], suggest that distinctive struc-
tural elements are required in S-prenyl derivatives for
the growth inhibition of Ras-transformed cells.
Taken together, these results demonstrate a posi-
tive correlation between the FTS-induced dislodg-
ment of farnesylated K-Ras 4B(12V) and growth in-
hibition of cells transformed by activated K-Ras 4B.
In this connection, it is important to note that K-Ras
4B can undergo S-prenylation by the enzyme gera-
nylgeranyltransferase I, especially under conditions
where the enzyme farnesyl transferase is blocked
[26^29]. Moreover, activated geranylgeranylated
Ras proteins exhibit transforming activity, most
probably because of their ability to associate with
the cell membrane and activate Ras-dependent sig-
naling pathways that lead to cell transformation
[13,15,30]. It was therefore of interest to examine
whether FTS can a¡ect geranylgeranylated K-Ras
4B and inhibit growth of cells transformed by this
Ras isoform. This was tested in cells that stably ex-
press the mutant K-Ras 4B(12V) CVIL, which serves
as a substrate for geranylgeranyltransferase I, but
Fig. 9. Dislodgment of K-Ras 4B(12V) isoforms from mem-
branes of K-Ras 4B(12V)-transformed NIH3T3 cells. NIH3T3
cells stably expressing K-Ras 4B(12V) or K-Ras 4B(12V) CVIL
were plated at a density of 4U106 cells/10-cm dish and grown
in 10% CS/DMEM. The K-Ras 4B(12V)/NIH3T3 cells received
25 or 50 WM GGTS for 24 h (A) and the K-Ras 4B(12V)
CVIL/NIH3T3 cells received 25 or 50 WM FTS for 24 h (B).
Cells were then homogenized and Ras proteins were determined
in the particulate fraction (P100) as detailed in [1]. Immunoblots
of a typical experiment are shown. Similar results were obtained
in two additional experiments. The mean decrease in K-Ras
4B(12V) was 25 þ 6% and 40 þ 10% in H-Ras(12V) in the pres-
ence of 25 and 50 WM GGTS, respectively. The mean decrease
in K-Ras 4B(12V)CVIL was 15 þ 8% and 35 þ 13% in the pres-
ence of 25 and 50 WM FTS respectively.
Fig. 8. Dose^response curves describing the growth inhibition
of cells expressing K-Ras 4B(12V) mutants by FTS and by vari-
ous S-prenyl derivatives. Cells were plated at a density of 2500
cells per well in 24-well plates, grown for 5 days in the presence
of the indicated concentrations of each derivative, and then
counted. Assays were performed in quadriplicate and the data
are presented as the ratio between the numbers of cells in drug-
treated cultures and in solvent-treated control cultures. Data
represent the means þ S.D. Results similar to those shown were
obtained in two to three additional experiments. (A). E¡ects of
FTS on the growth of NIH3T3 cells and of NIH3T3 cells
transformed by K-Ras 4B(12V) or by K-Ras 4B(12V) CVYM.
(B). E¡ects of FTS on the growth of cells expressing K-Ras
4B(12V) SVIM or K-Ras 4B(12V) CVIL. (C). E¡ects of various
S-prenyl analogs on the growth of K-Ras 4B(12V)/NIH3T3
cells.
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not for farnesyltransferase [14,15]. As shown in Fig.
9B, FTS induced a signi¢cant reduction (37% at 50
WM) in the amount of membrane K-Ras 4B(12V)
CVIL. FTS also inhibited, in a dose-dependent man-
ner, the growth of the K-Ras 4B(12V) CVIL/
NIH3T3 cells (Fig. 8B), suggesting that FTS can
a¡ect K-Ras 4B functions whether it is farnesylated
or geranylgeranylated.
4. Discussion
As with all Ras proteins, membrane anchorage of
K-Ras 4B is promoted by its carboxy-terminal S-
farnesylcysteine carboxy methyl ester, but unlike H-
Ras, N-Ras and K-Ras 4A, in which membrane an-
chorage also requires palmitoylation, K-Ras 4B re-
quires its sequence of six lysine residues adjacent to
the farnesylated cysteine [3,10^15]. In earlier studies,
we found that the constitutively active form of the
more heavily lipidated H-Ras(12V) protein can be
dislodged from the cell membrane by FTS [23,24].
We postulated that the e¡ect of FTS could represent
interference of the drug in the interaction between
the S-farnesyl moiety of H-Ras and a speci¢c mem-
brane-anchorage domain. This possibility was sup-
ported by experiments demonstrating that interfer-
ence with H-Ras(12V) functions requires the
presence of distinctive structural elements in S-prenyl
analogs of FTS [21,25], as well as by experiments
demonstrating a lack of FTS e¡ects on the geneti-
cally engineered N-myristoylated (unfarnesylated)
Ras protein [24]. The hypothesis predicted that
FTS, which resembles the structure of the S-farnesyl-
cysteine common to all Ras proteins, would also in-
terfere with membrane association of K-Ras 4B,
which is not lipidated by lipids other than a farnesyl
group. The present work demonstrates that this is
indeed the case. It shows that FTS can dislodge
K-Ras 4B(12V) from putative anchorage sites in
the membrane (Fig. 1) and accelerate its rate of deg-
radation (Fig. 2). These e¡ects were accompanied by
a decrease in the total amount of K-Ras 4B(12V)
(Fig. 4) and inhibition of ERK activity in the
K-Ras 4B(12V)-transformed cells (Figs. 5 and 6)
and inhibition of cell growth (Figs. 7 and 8).
The FTS-induced decrease in K-Ras 4B(12V) and
in ERK activity occurred at the concentration range
(5^50 WM) at which FTS inhibited growth of the
K-Ras 4B(12V)-transformed cells (Figs. 7 and 8). A
similar correlation was described in cells transformed
by H-Ras(12V) [21,25,35], a Ras isoform that is both
farnesylated and palmitoylated [3,10^15]. It thus ap-
pears that growth inhibition of Ras-transformed cells
by FTS is primarily associated with its ability to
disrupt the interactions between the S-farnesyl moi-
ety of Ras proteins and the cell membrane. It is
certainly possible that FTS may inhibit the growth
of some Ras-transformed cells because their prolifer-
ation is driven by a number of prenylated proteins,
not because it is being driven by Ras speci¢cally.
Indeed, in some cases, this may be true, and we do
not mean to suggest here that it cannot be so. How-
ever, the likely existence of other prenylated target
proteins does not alter the importance of the ¢nding
that, where the growth of transformed cells is driven
by activated K-Ras, as it is in the NIH cell lines
studied here, FTS (but not FTI) can inhibit their
growth. It is also important to re-iterate that FTS
does not inhibit the growth of every type of a trans-
formed cell line. We showed in a previous study that
SV40 T-antigen transformed cells were not inhibited,
whereas ErbB2-transformed cells were [23]. It is well
established that T-antigen transformation is not de-
pendent upon Ras (although they can cooperate),
whereas ErbB2 transformation, by contrast, is de-
pendent upon Ras function. These data provide ad-
ditional support for the idea that inhibition of Ras
function has a greater in£uence in determining sensi-
tivity to FTS growth inhibition than does transfor-
mation in general. In addition to these results, we
have also shown evidence that the growth of cells
transformed by a myristoylated (non-prenylated)
form of Ras is not a¡ected by FTS treatment [24].
These cells are every bit as rapidly growing as cells
transformed by farnesylated Ras proteins and thus
represent an excellent control for the growth inhib-
itory action of FTS due to inhibition of prenylated
Ras.
Support for the notion that the mechanism of ac-
tion of FTS is associated primarily with its e¡ects on
membrane-bound K-Ras 4B(12V) or membrane-
bound H-Ras(12V) [24] comes from additional ex-
periments in the present study. Previous studies
have shown that farnesylation of K-Ras 4B(12V) is
su⁄cient for its membrane anchorage and transform-
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ing activity. This is because the K-Ras 4B(12V)
CVYM mutant presents activities similar to those
of K-Ras 4B(12V) mutant, yet its VYM tripeptide
is not removed by the CAAX protease and thus
K-Ras 4B(12V) CVYM is not carboxyl methylated
[14]. Here we show that FTS induces a decrease in
the amount of K-Ras 4B(12V) CVYM (Fig. 4) and
inhibits the growth of cells transformed by this Ras
mutant (Fig. 8). Clearly, then, growth inhibition by
FTS cannot be ascribed to inhibition of the CAAX
protease or to inhibition of the methyltransferase.
This conclusion is consistent with earlier studies
demonstrating that FTS does not inhibit H-Ras
methylation in intact cells at the concentration range
at which it inhibits cell growth [23]. It is also impor-
tant to note that FTS does not inhibit farnesylation
of H-Ras by the enzyme farnesyltransferase [23].
Although we did not test this directly with mutants
of K-Ras 4B, it is very unlikely that FTS inhibited
their farnesylation. Such an e¡ect would have caused
accumulation of unprocessed K-Ras 4B in the cyto-
sol [31], and this was not observed in our experi-
ments (Fig. 1). As a ¢nal point in connection with
post-translational modi¢cations in Ras proteins, it is
worth reiterating that the observed FTS-induced dis-
lodgment (Fig. 1) and accelerated degradation (Fig.
2) of K-Ras 4B(12V) clearly demonstrate that the
e¡ect of the drug is independent of Ras palmitoyla-
tion. Together with previous ¢ndings on H-Ras
(12V), the present data indicate that FTS a¡ects
the mature membrane-bound forms of Ras proteins
and not their processing. This emphasizes the sub-
stantial di¡erence between the mechanism of action
of FTS and of farnesyltransferase or geranylgeranyl-
transferase inhibitors that inhibit Ras processing [36^
41].
The precise mechanism through which FTS and its
active analogs a¡ect Ras-membrane interactions
(Figs. 1 and 2) and subsequently inhibit the growth
of H-Ras-transformed [21,23,24] and K-Ras-trans-
formed cells (Figs. 7 and 8) is not yet known. We
do know, however, that this mechanism involves a
rather speci¢c disruption of Ras-membrane anchor-
age. First, growth inhibition of cells that express ac-
tivated Ras isoforms by prenyl analogs clearly de-
pends on the structure of such analogs. For
example, farnesol, farnesoic acid, S-farnesylthiopro-
pionic acid, AFC, and the C10 S-prenyl derivative
GTS do not inhibit the growth of H-Ras-trans-
formed cells, whereas FTS, its 5-£uoro and 5-chloro
derivatives, and the C20 derivative GGTS are active
inhibitors [25]. Similar structure^activity relation-
ships were observed here in K-Ras 4B(12V)-trans-
formed cells (Fig. 8) and in Panc-1 cells that express
activated K-Ras(12V) [42]. Second, the genetically
engineered N-myristoylated (unfarnesylated) Ras
mutant that is inserted non-speci¢cally into the cell
membrane is not a¡ected by FTS in vivo [24] or in
vitro (Fig. 1). This suggests interference by FTS with
the interactions between the S-farnesylcysteine of
Ras and speci¢c membrane-anchorage sites. Both
wild-type Ras and activated Ras proteins were found
to be localized in speci¢c membrane domains such as
caveolae, or related domains enriched in glycosphin-
golipids and cholesterol [17^20]. FTS may exert its
e¡ect by interfering with the interactions between
Ras and a Ras-binding protein [43] or between Ras
and speci¢c lipids or proteins present in caveolae or
related membrane domains. Third, we recently ob-
served that FTS can alter the lateral mobility of
the green-£uorescent K-Ras 4B(12V) fusion protein
(GFP-K-Ras) with no e¡ect on the bulk of the mem-
brane lipids in the membranes of live cells [44]. These
observations, together with the knowledge that Ras
proteins are localized in membrane microdomains
[17^20], also suggest that FTS targets H-Ras [24]
and K-Ras (Figs. 1 and 2) associated with lipids
and/or proteins of glycosphingolipid/cholesterol-en-
riched domains. In this connection it is interesting
to note that FTS inhibited the growth of cells trans-
formed by the geranylgeranylated K-Ras 4B(12V)
CVIL mutant (Fig. 8B). These data, along with the
ability of GGTS to mimic the actions of FTS (Fig.
8C), suggest that Ras-recognition domains in the cell
membrane can tolerate an extended (C20) S-prenyl
moiety.
Since most GLQ subunits of the heterotrimeric G-
proteins are geranylgeranylated, the previously ob-
served lack of FTS e¡ect on these membrane-associ-
ated proteins [24] could have led to the expectation
that FTS will not a¡ect membrane-bound geranyl-
geranylated-Ras. This, however, was not the case
(Fig. 9). A possible explanation for these observa-
tions is that K-Ras 4B and GLQ localize to distinct
membrane domains or anchor di¡erently within a
same microdomain. The geranylgeranylated K-Ras
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4B(12V) would then associate, like farnesylated K-
Ras 4B(12V), with domains that preferentially asso-
ciate Ras and not GLQ. Recent experiments demon-
strated distinct membrane domains in mouse mela-
noma B16 cells where Rho A and c-Src were found
to be localized in GM3-enriched fractions, whereas
Ras and caveolin were found to be localized in glu-
cosylceramide/cholesterol-enriched domains [45].
These experiments and the recent observations that
even K-Ras and H-Ras appear to associate with dif-
ferent membrane domains [46] make the above ex-
planation possible, though other possibilities cannot
be ruled out.
It is worth noting that the e¡ects of S-prenyl ana-
logs, such as FTS on Ras are manifested not only in
a decrease in the amount of membrane-bound Ras.
We know of at least two additional FTS-related ef-
fects on Ras. The ¢rst was detected in experiments
with GFP-K-Ras, where we found that following
FTS treatment the residual Ras in the cell membrane
presents impaired membrane interactions [44]. More
speci¢cally, we found that FTS has a biphasic e¡ect
on GFP-K-Ras lateral mobility. At the initial phase,
the lateral di¡usion rate of GFP-K-Ras was elevated,
suggesting that it is released from some constraints
on its lateral mobility. This was followed by dislodg-
ment of the protein into the cytoplasm, and reduc-
tion in the di¡usion rate of GFP-K-Ras that re-
mained associated with the plasma membrane. This
is important because in all types of cells tested so far,
we ¢nd that FTS reduces the amount of Ras only by
50^80% [23,24]. A signi¢cant amount of activated
H-Ras [24] or K-Ras (Figs. 1 and 3) therefore re-
mains in the cell membrane. The above observation
suggests that in addition to the FTS-induced reduc-
tion in the amounts of active Ras, FTS disrupts the
interaction of residual Ras with the membrane. An
additional FTS-related e¡ect is the drug-facilitated
degradation of H-Ras(12V) [24] and of K-Ras
4B(12V) (Fig. 3). This e¡ect certainly explains why
the total amount of Ras is reduced in FTS-treated
cells. It also suggests that dislodgment of Ras from
its putative anchorage sites by FTS renders the pro-
tein susceptible to proteolytic degradation. We do
not know, however, whether or not degradation of
Ras is accomplished by unique enzymes. The data
demonstrating that FTS-accelerated degradation of
the fully processed K-Ras 4B(12V) (Fig. 2), but not
of the unprocessed K-Ras 4B(12V) SVIM mutant
(Fig. 3), along with the latter’s very slow degradation
rate, suggest that speci¢c degradation of Ras requires
its farnesyl moiety. The precedence of the CAAX
protease, which acts speci¢cally on farnesylated Ras
proteins [47], is an example of such a requirement in
a proteolytic enzyme.
The present study provides mechanistic explana-
tions for the action of FTS on Ras and points to
the signi¢cance of putative Ras-anchorage sites with-
in membrane domains. It may also have important
therapeutic implications. K-Ras 4B is the major al-
ternative splice product of the mammalian K-Ras
gene [8]. This Ras isoform and the N-Ras isoform
are the most frequently detected Ras oncoproteins in
human tumors [7,8]. Compounds that a¡ect K-Ras
and N-Ras oncoproteins may therefore be considered
as potential anti-cancer drugs. FTS, with its ability
to a¡ect H-Ras(12V) [23^25], K-Ras 4B(12V) (Figs.
1^3) and N-Ras (B. Jansen and Y. Kloog, unpub-
lished observations), seems to represent such a po-
tential anti-tumor drug. It is important to note in
this connection that K-Ras 4B and N-Ras can act
as substrates for the enzyme geranylgeranyltransfer-
ase I [26^29], and that they are indeed geranylgera-
nylated when farnesyltransferase activity is blocked
by speci¢c inhibitors [28,29]. Because constitutively
active geranylgeranylated Ras proteins are active bi-
ologically, it seems that the inhibition of cell and
tumor growth by farnesyltransferase inhibitors is
caused by the inhibition of as yet unknown farnesyl-
ated proteins, and not by the direct blockage of K- or
N-Ras functions [3]. As we have indicated in the
current manuscript, the claim for the importance of
inhibition of K-Ras 4B comes from two types of
results. First, FTS does not inhibit the growth of
Raf-transformed cells or cells transformed by T-anti-
gen [23]. Second, in the same publication and in re-
lated studies [23], we have demonstrated clearly that
FTS does not block the growth of normal cells.
Therefore, the ability of FTS to inhibit the growth
of Ras- but not Raf-transformed cells argues that
Ras- but not Raf-transformed or normal cell growth
is indeed driven by a prenylated protein which can be
inhibited by FTS. In the case of the cells tested here,
the most important prenylated protein is K-Ras 4B.
In other cell types (not Raf-transformed or normal
cells) other prenylated proteins may be important.
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The fact that FTS can target K-Ras, which is insen-
sitive to inhibition by FTIs, suggests that FTS may
target Ras (and any other prenylated proteins impor-
tant for transformed cell growth) in an e⁄cient man-
ner that speaks well for its potential as an anti-cancer
therapeutic agent. This possibility, and the present
results demonstrating that FTS inhibits the growth
of cells transformed by geranylgeranylated K-Ras
4B, also suggest that a combined treatment of FTIs
and FTS might result in synergistic inhibitory e¡ects
on cells transformed by K-Ras 4B or by N-Ras.
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